TheranosticTrials.org

Clinical Trial · NCT00850278

Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors

Overview

The primary objective of this study is to assess the efficacy of the radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a tracor of cell proliferation, using Positron Emission Tomography (PET) imaging for the tumor diagnosis and prognosis in a group of 50 patients with different type of brain tumors.\[F-18\]FLT PET imaging will be compared to the current used imaging techniques of MRI, spectroscopy imaging, PET imaging using \[11C\]MET tracer, immunohistochemical analysis and clinical parameters.

Sponsor

University Hospital, Ghent

Phase

N/A

Contacts

Jean-Michel Derlon, Pr (STUDY_DIRECTOR)

Jean-Sébastien Guillamo, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00850278

Drug / Compound

FLT

Isotope(s):
Target(s):
  • cytosolic thymidine kinase 1
Ligand Class: Small Molecules

Eligibility

Inclusion

  • the following laboratory results : absolute neutrophil count \>= 1500 cells/µl, platelet count \>= 100000 cells/µl, SGOT \<= 2.5 x ULN, serum creatinine \<= 1.5 x ULN.
  • must have adequate liver and kidney function
  • KPS \>= 70%

Exclusion

  • concomitant radio-, chemo-, or immunotherapy
  • patient with hepatitis B or C